GLP-1 Special Series
By VETTAPHARMA reporter: In 2025, cardiovascular medicine witnessed a growing tide of evidence that medications originally developed for diabetes are reshaping heart disease outcomes — and regulators are taking notice.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide, have long been prescribed for glycemic control and weight loss. In recent randomized trials and meta-analyses, these drugs have demonstrated meaningful benefits beyond metabolic effects, including reductions in major cardiovascular events and improvements in clinical outcomes for individuals with high cardiovascular risk.
Patient Population and Study Design
A 2025 systematic review and meta-analysis published in BMC Cardiovascular Disorders synthesized randomized controlled trials (RCTs) of semaglutide in adults with type 2 diabetes mellitus (T2DM) and elevated cardiovascular risk, including those with established atherosclerotic disease. This open-access evidence encompassed tens of thousands of participants across multinational phase 3 trials. The RCTs compared semaglutide versus placebo in addition to standard of care over periods ranging from 1.5 to 3+ years.
Primary Endpoints
The primary endpoints across these studies included major adverse cardiovascular events (MACE) — a composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke — as well as all-cause mortality and cardiovascular event rates. Safety endpoints examined serious adverse events, gastrointestinal tolerability, and changes in metabolic and hemodynamic markers.
Key Findings
Cardiovascular Risk Reduction: Semaglutide was associated with a statistically significant reduction in MACE compared with placebo in adults at high cardiovascular risk, translating into meaningful cardioprotection beyond glycemic control.
Mortality and Safety: Meta-analytic data showed lower all-cause and cardiovascular mortality rates in patients treated with GLP-1 RAs, with an overall favorable safety profile — though gastrointestinal adverse reactions were more common.
Regulatory Context: Approvals in the US and EU
United States (FDA):
In March 2024, the U.S. Food and Drug Administration approved an expanded indication for Wegovy (semaglutide injection) to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and obesity or overweight — based on a large multinational, placebo-controlled, double-blind RCT involving the specified patient population. This landmark approval recognized semaglutide not only for weight management but for cardiovascular risk reduction in patients at high risk.
European Union (EMA):
The EMA has recognized that GLP-1 receptor agonists, including semaglutide-based medicines, show evidence of cardiovascular benefit; however, it has historically not granted a distinct cardiovascular disease indication separate from their existing labels for diabetes management or weight control. For example, Wegovy (semaglutide) remains authorised in the EU for weight management in adults with obesity or overweight (BMI ≥ 30 or ≥ 27 kg/m² with comorbidities, including cardiovascular disease) as an adjunct to diet and exercise, and although cardiovascular outcome data have been submitted, a separate primary cardiovascular indication was not approved — instead, the product information will be updated to include relevant trial results to inform clinicians.
By contrast, at the CHMP meeting from 26–29 January 2026, the committee reviewed Eli Lilly and Company’s tirzepatide (Mounjaro) data submitted to extend use into symptomatic chronic heart failure with preserved ejection fraction (HFpEF) in adults with obesity. While a separate indication for HFpEF was not granted, CHMP agreed to incorporate efficacy and safety results into the product information so that prescribers can consider the evidence in this cardiovascular population.
Additionally, the EMA’s CHMP has approved updates to the label of Rybelsus (oral semaglutide) to reflect cardiovascular benefits observed in the SOUL trial, making it the first oral GLP-1 RA in the EU with a recognised reduction in cardiovascular death, heart attack, and stroke in adults with type 2 diabetes at high cardiovascular risk.
Conclusion
Emerging 2025 evidence from large RCTs and meta-analyses supports a paradigm shift: GLP-1 RAs like semaglutide not only improve metabolic parameters but also reduce cardiovascular risk in high-risk populations. Regulatory bodies reflect this in evolving labels, especially in the U.S., where cardiovascular benefit is now an approved indication. Safety profiles remain consistent with known class effects, underscoring the importance of personalized clinical decision-making.
Source credit:
- BMC Cardiovascular Disorders. (2025, November 21). Cardiovascular benefits of semaglutide: a systematic review and meta-analysis of randomized controlled trials.
- Galli, A. et al. (2025). Cardiovascular effects and tolerability of GLP-1 receptor agonists: a systematic review and meta-analysis of 99,599 patients. American College of Cardiology Foundation.
- U.S. Food and Drug Administration. (2024, March 8). FDA approves first treatment to reduce risk of serious heart problems specifically in adults with obesity or overweight.
- European Medicines Agency. (2024). Outcome of assessment: extension of use for Wegovy (semaglutide).
- European Medicines Agency. (2026, January 30). Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 26–29 January 2026.
Disclaimer:
The contents published on this platform are intended solely for informational and educational purposes. Reports, summaries, and discussions related to clinical trials are based on publicly available data, press releases, scientific publications, and regulatory disclosures available at the time of reporting. The information provided does not constitute medical advice, diagnosis, treatment recommendations, or endorsement of any drug, therapy, or clinical outcome. Clinical trial data are subject to change as studies progress, and results discussed may be preliminary, incomplete, or not yet peer-reviewed. Readers are strongly encouraged to refer to the original clinical trial records, regulatory filings, peer-reviewed articles or related sources for complete, accurate, and up-to-date information. Healthcare professionals and patients should consult qualified medical professionals and relevant regulatory authorities before making any healthcare or treatment decisions. Images used on this platform are illustrative in nature and are intended for conceptual and representational purposes only. They may not depict actual products, facilities, individuals, or events. The platform and its contributors disclaim any liability for actions taken based on the information presented.
